Enzo Biochem, Inc.
New York Stock ExchangeCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Kara Cannon
- Full Time Employees
- 125
- Sector
- Healthcare
- Industry
- Medical - Diagnostics & Research
- Address
- 527 Madison Avenue New York City NY United States of America 10022
- IPO Date
- Jun 12, 1980
- CIK
- 0000316253
- Website
- enzo.com
- Similar Companies
- Business
- Enzo Biochem, Inc. (ENZ) is a life sciences company specializing in labeling and detection technologies for genomic, protein, cell, and tissue analysis. The company offers a comprehensive portfolio of over 6,000 proprietary products, including antibodies, genomic probes, immunoassays, biochemicals, proteins, dyes, and labeling kits; these tools support applications in translational research, drug discovery, drug development, cell biology, genomics, immunohistochemistry, small molecule chemistry, and nucleic acid detection. Enzo Biochem also provides custom manufacturing services, GMP services, assay and validation testing, and licensing of its technologies, serving academic researchers, biotechnology firms, pharmaceutical companies, and diagnostic manufacturers worldwide through offices in the United States, Switzerland, Germany, France, the United Kingdom, and Benelux regions. Founded in 1976 and headquartered in Farmingdale, New York, the company operates primarily through its Enzo Life Sciences division, leveraging over 500 patents, in-house U.S. manufacturing, and a workforce with more than 25% PhD scientists to deliver rigorously validated, high-sensitivity products cited in over 175,000 publications. In June 2025, Enzo Biochem entered into a definitive merger agreement to be acquired by Battery Ventures for approximately $37 million, or $0.70 per share in cash, following a strategic review by a special committee of its Board of Directors; the take-private transaction was completed in August 2025, transitioning the company to private ownership under Battery Ventures to support accelerated innovation, R&D investment, market expansion, and targeted acquisitions. Concurrent with the acquisition, veteran life sciences executive Jason Apter joined as Group CEO, backed by Battery partners on the board including Justin Rosner, Jesse Feldman, and Alan Hirzel. In fiscal year 2025, the company launched approximately 100 new products per quarter amid life sciences sector challenges, reported sequential revenue improvements to $7.3 million in Q2, and maintained focus on cost containment and product lifecycle maintenance.
Enzo Biochem, Inc. To be Acquired by Battery Ventures in All-Cash Transaction
Enzo Biochem Reports Third Quarter Fiscal Year 2025 Results
Enzo Biochem, Inc. Announces Review of Strategic Alternatives after Receiving Multiple Inquiries Regarding a Potential Transaction
The Zacks Analyst Blog AbbVie, The TJX, The Charles Schwab, Enzo Biochem and CVD Equipment
Enzo Biochem Announces Notification to New York Stock Exchange of Intention to Voluntarily Delist Common Stock and Transfer Trading of Shares to OTCQX
Enzo Biochem Reports Second Quarter Fiscal Year 2025 Results
Enzo Biochem Receives Notice of Non-Compliance with New York Stock Exchange Listing Rules
ENZ Stock Falls Post Q1 Earnings Amid Revenue and Demand Challenges
Enzo Biochem Reports First Quarter Fiscal Year 2025 Results and Provides a Company Update
ENZ Stock Up Following FY24 Earnings Uptick, Gross Margin Expands
Enzo Biochem Reports Fourth Quarter and Fiscal Year 2024 Results and Announces Cash Dividend
Enzo Biochem to pay $4.5 mln for failing to safeguard patient data
Enzo Biochem: Is This Time Finally Different?
Zacks Initiates Coverage of Enzo Biochem With Neutral Recommendation
Enzo Biochem (ENZ) Q3 Earnings Improve Y/Y, Gross Margin Up
Enzo Biochem Reports Third Quarter Fiscal 2024 Results and Provides Business Update
Enzo Biochem Reports Second Quarter Fiscal 2024 Results and Provides Business Update
Enzo Biochem Reports Results of its Annual Meeting of Shareholders and Officer Appointments
ENZO BIOCHEM REPORTS FIRST QUARTER FISCAL 2024 RESULTS AND PROVIDES BUSINESS UPDATE
Steven J. Pully Appointed to Enzo Biochem's Board of Directors